|Bid||150.50 x 800|
|Ask||157.00 x 800|
|Day's Range||150.74 - 155.60|
|52 Week Range||95.65 - 164.76|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||179.20|
Evidence that cannabis can ease epilepsy and other conditions is building as a British company counts down to what would be the first U.S. government approval for a prescription drug derived from the marijuana plant. GW Pharmaceuticals (GWPH.O), which has spent 20 years developing medicines from cannabis, is hoping for a Food and Drug Administration (FDA) green light by June 27, after winning support from an advisory panel in April. Some parents already use cannabis to help children with severe forms of epilepsy, but such therapy is not monitored or licensed.
Evidence that cannabis can ease epilepsy and other conditions is building as a British company counts down to what would be the first U.S. government approval for a prescription drug derived from the marijuana plant. GW Pharmaceuticals, which has spent 20 years developing medicines from cannabis, is hoping for a Food and Drug Administration (FDA) green light by June 27, after winning support from an advisory panel in April. "We've learnt a huge amount about cannabis," said Valerie Curran, head of the clinical psychopharmacology unit at University College London.
NEW YORK, NY / ACCESSWIRE / June 20, 2018 / As Canada officially legalized recreational marijuana this week, shares of Canopy Growth skyrocketed after announcing a multi-year agreement with Neptune Technologies & Bioressources Inc. Shares of GW Pharmaceuticals were modestly in the red despite any news. Canopy Growth Corporation shares closed up almost 4% on Tuesday with nearly 4.5 million shares traded. The stock hit a brand new high of $32.88 yesterday after it was revealed that Neptune Technologies & Bioressources Inc. has entered into a multi-year agreement with Canopy Growth to supplement Canopy Growth's extraction, refinement, and extract product formulation capacity.
COLORADO SPRINGS, Colo. (AP) — Some American parents who for years have used cannabis to treat severe forms of epilepsy in their children are feeling more cautious than celebratory as U.S. regulators near a decision on whether to approve the first drug derived from the marijuana plant.
The former, a large swath of the global population, is tainted by 90 years of misinformation that’s been perpetuated by those benefiting from the status quo, which began with William Randolph Hearst defending his paper empire and continues with big pharma protecting their prescriptions.They view cannabis as a gateway drug or cite moral conflicts and the conversation ends there. We believe many of them will evolve into late-cycle adopters that provide future layers of demand.
The news that GW Pharmaceuticals PLC (ADR) (NASDAQ:GWPH) will soon see Epidiolex, the company’s experimental drug that treats epilepsy, is fantastic in and of itself. Here’s why Epidiolex’s approval should matter to everyone participating in the burgeoning cannabis industry and not just GWPH shareholders. The biggest problem facing the cannabis industry at the moment as it pertains to Cannabidiol (CBD), the main ingredient of Epidiolex, is that hemp-derived CBD is technically considered legal throughout the U.S. as a result of the Agricultural Act of 2014 and exempted from Drug Enforcement Administration (DEA) regulation under a 2006 law, while marijuana-derived CBD is only legal in 30 states and Washington, D.C.
Bitcoin Untethered, Literally Speculation is mounting that the price of bitcoin (BTC-USD) and other altcoins like ethereum (ETH-USD) and bitcoin cash (BCH-USD) has been manipulated using a scheme pretty much identical to what the Federal Reserve uses to inflate the price of US treasuries. Tether (USDT-USD), a crytpocurrency token supposedly backed by, or “tethered” to […] The post Market Morning: Bitcoin Untethered, Fed Talks Marijuana, Whole Amazon Foods Clash appeared first on Market Exclusive.
The marijuana industry is blooming at present, following the legalization of both medical and now recreational cannabis in Canada.
GW Pharmaceuticals plc (GWPH) (GW, the Company or the Group), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announced that GW management will present at the Goldman Sachs 39th Annual Global Healthcare Conference on Wednesday, June 13, 2018 at 10:00 a.m. PT at the Terranea Resort, in Rancho Palos Verde, CA. Founded in 1998, GW is a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas.
NEW YORK, June 06, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Clementia ...
Which stock wins in a match-up between a big supplier to the marijuana industry and the world's top marijuana biotech?
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Biotech stocks hitting 52-week highs on May 29) Ascendis Pharma A/S (NASDAQ: ASN ) ASLAN PHARMACEUTICALS ...
This year has been a mixed bag for marijuana stocks. After an initial rally at the start of this year, marijuana stocks have mostly been on a downward slide. The North American Marijuana Index, which is a basket of 41 tickers spanning the marijuana supply chain, is down by 19% since the start of this year, as of this writing.
Examining how GW Pharmaceuticals plc (NASDAQ:GWPH) is performing as a company requires looking at more than just a years’ earnings. Below, I will run you through a simple sense checkRead More...
NEW YORK, NY / ACCESSWIRE / May 24, 2018 / U.S. markets rebounded modestly on Wednesday, following the release of Fed's minutes of the meeting, which suggest that the central bank will be slightly dovish ...
“A key development for the US Marijuana industry came on April 13th, when President Trump confirmed he had promised Colorado Senator Cory Gardner that US AG Jeff Sessions revocation of the Cole memo will not affect the state's legal Marijuana industry,” said IHS Markit in a recent research note. “That was a very timely update, with the combined market cap for Marijuana related stocks hitting a 2018 low on April 9th. Home to over $380 million in assets under management, MJ tracks the Prime Alternative Harvest Index.
No pain, big gain? There could be an untapped market for cannabinoids that biotechs aren't aggressively pursuing yet.